Table 1.
Correlations between lncRNA RP11‐466I1.1 expression and the clinicopathological variables of patients with HCC
| Characteristic | No. of patients (N = 72) | lncRNA RP11‐466I1.1 expression | P value | |
|---|---|---|---|---|
| Low | High | |||
| Age (y) | ||||
| <50 | 29 | 16 | 13 | .4710 |
| ≥50 | 43 | 20 | 23 | |
| Sex | ||||
| Male | 48 | 23 | 25 | .6171 |
| Female | 24 | 13 | 11 | |
| Tumor size | ||||
| <5 cm | 28 | 11 | 17 | .1469 |
| ≥5 cm | 44 | 25 | 19 | |
| Cirrhosis | ||||
| Positive | 38 | 15 | 23 | .0590 |
| Negative | 34 | 21 | 13 | |
| Histological grade | ||||
| Good | 14 | 12 | 2 | .0049** |
| Moderate | 43 | 20 | 23 | |
| Poor | 15 | 4 | 11 | |
| Metastasis | ||||
| With | 18 | 6 | 12 | .1025 |
| Without | 54 | 30 | 24 | |
| Tumor capsule | ||||
| Complete | 26 | 22 | 14 | .0055** |
| Incomplete | 46 | 14 | 32 | |
| AFP (ng/mL) | ||||
| ≤20 | 40 | 24 | 16 | .0578 |
| >20 | 32 | 12 | 20 | |
| CEA (ng/mL) | ||||
| ≤10 | 58 | 30 | 28 | .5515 |
| >10 | 14 | 6 | 8 | |
| γ‐GT (U/L) | ||||
| ≤40 | 20 | 12 | 8 | .2926 |
| >40 | 52 | 24 | 28 | |
| Child‐Pugh classification | ||||
| A | 68 | 35 | 32 | .3570 |
| B | 5 | 1 | 4 | |
| C | 0 | 0 | 0 | |
| BCLC staging | ||||
| 0 | 11 | 8 | 3 | .1901 |
| A | 61 | 28 | 33 | |
| B/C/D | 0 | 0 | 0 | |
AFP, α‐fetoprotein; CEA, carcinoembryonic antigen; HCC, hepatocellular carcinoma; γ‐GT, γ‐glutamyl transpeptidase.
For the expression of lncRNA RP11‐466I1.1, median expression level was used as the cutoff. Data were analyzed by chi‐squared test. The difference was statistically significant when P < .01 (**) or P < .05 (*).